Dallas is focusing on new and advanced treatments, like those that use cells or genes. They are also looking at how biology ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...

The SBIO ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness.

HK Innoen announced on the 26th that it received the highest grade (AA) in the "2025 Second Half ESG Evaluation Results" ...

The global bioreactor market is projected to grow at a compound annual growth rate (CAGR) of around 7%, driven by the rising ...

On November 20, 2025, at a closed-door, Q&A webinar on the proposed BIOSECURE Act, Joy Sturm, partner in the Hogan Lovells government ...

Urban areas face unprecedented challenges due to climate change, biodiversity loss, and rapid population growth. In this ...

Every year, the fields of fisheries and aquaculture generate substantial quantities of leftover biomass, including heads, ...

Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR? Antagonist, Phase 3-ready) and ...

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the frst FDA-approved ...

Sport P.E.I. has launched a new Performance Hub for testing young athletes. The goal is to give coaches, trainers and athletes information to help improve future performances. The equipment will also ...